Oxford BioMedica ( (GB:OXB) ) has issued an update.
Oxford Biomedica announced that its Chief Financial Officer, Dr. Lucinda Crabtree, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2025. This participation highlights OXB’s active engagement in the global healthcare community and reinforces its position as a leader in the cell and gene therapy industry.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, OXB is a pioneer in viral vector development, collaborating with leading pharmaceutical and biotechnology companies. The company offers expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vectors, providing services from early-stage development to commercialization. Headquartered in Oxford, UK, OXB operates facilities in the UK, France, and the US.
YTD Price Performance: -19.98%
Average Trading Volume: 6,957
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $448.1M
For a thorough assessment of OXB stock, go to TipRanks’ Stock Analysis page.